View Older Stories View More Recent Stories

Nov 6, 2018 04:36PM Bristol-Myers Squibb (BMY) Announces Approves Empliciti Plus Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Nov 6, 2018 04:34PM U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myelo
Nov 5, 2018 07:00AM Bristol-Myers Squibb (BMY), Infinity Pharmaceuticals (INFI) Reports New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Nov 5, 2018 06:59AM Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Nov 5, 2018 06:59AM Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Oct 25, 2018 08:15AM Halozyme Therapeutics (HALO) Reports First Clinical Dosing In Bristol-Myers Squibb (BMY) Phase 1 Trial Of BMS-986179 With Enhanze Technology
Oct 25, 2018 08:00AM Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology
Oct 25, 2018 06:59AM Bristol-Myers Squibb Reports Third Quarter Financial Results
Oct 22, 2018 06:45AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Oct 22, 2018 06:00AM Bristol-Myers Squibb (BMY) Reports Data from Phase 3 CheckMate -067 Clinical Trial for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab)
Oct 22, 2018 03:20AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma
Oct 22, 2018 03:15AM Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Oct 20, 2018 03:15AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer
Oct 19, 2018 04:17PM Bristol-Myers Squibb (BMY) Provides Update on Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy
Oct 19, 2018 04:16PM Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden ≥10 mut/Mb
Oct 17, 2018 06:59AM Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annu
Oct 12, 2018 07:00AM Bristol-Myers Squibb (BMY) Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of OS with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed SCLC
Oct 12, 2018 06:59AM Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell L
Oct 11, 2018 07:00AM Bristol-Myers Squibb (BMY) and Compugen (CGEN) Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Oct 11, 2018 06:59AM Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Oct 11, 2018 06:59AM Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Sep 18, 2018 07:12AM Bristol-Myers Squibb (BMY) Announces EMA Validates its Application for Empliciti Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Sep 18, 2018 06:59AM European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Sep 18, 2018 06:59AM European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Sep 13, 2018 01:05PM Natera (NTRA) Enters Agreement with Bristol-Myers (BMY) for Signatera ctDNA Assay
Sep 12, 2018 04:10PM Bristol-Myers Squibb Announces Dividend
Sep 12, 2018 05:59AM Bristol-Myers Squibb (BMY) Reports 'Significant Skin Clearance' from Phase 2 Study of BMS-986165 in Patients with Moderate to Severe Plaque Psoriasis
Sep 12, 2018 02:01AM Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
Sep 6, 2018 03:00PM Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Sep 6, 2018 06:59AM Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25
Sep 5, 2018 06:59AM Bristol-Myers Squibb Kicks Off Coast 2 Coast 4 Cancer Ride to Fundraise for the V Foundation for Cancer Research
Aug 30, 2018 07:01AM Bristol-Myers Squibb (BMY) Reports FDA Approval of Supplemental Biologics License Application for Sprycel (dasatinib) in Pediatric Patients
Aug 30, 2018 06:59AM U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
Aug 28, 2018 09:00AM Bristol-Myers Squibb Appoints Christopher Boerner Executive Vice President and Chief Commercial Officer
Aug 23, 2018 07:00AM Bristol-Myers Squibb (BMY) Says FDA Accepts for Priority Review of its Application for Empliciti Plus Pomalidomide and Low-Dose Dexamethasone in Patients with RRMM
Aug 23, 2018 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or
Aug 17, 2018 07:00AM Bristol-Myers Squibb (BMY) Says FDA Approved Opdivo as First New Medication in Nearly 20 Years for Certain Patients with Previously Treated SCLC
Aug 17, 2018 06:59AM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer
Jul 31, 2018 07:00AM Bristol-Myers Squibb (BMY) Reports EMA Approval for Opdivo (nivolumab)
Jul 31, 2018 06:59AM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Under
Jul 26, 2018 06:59AM Bristol-Myers Squibb Reports Second Quarter Financial Results
Jul 24, 2018 07:00AM Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer
Jul 23, 2018 08:30AM Bristol-Myers Squibb Announces Departure of Chief Commercial Officer
Jul 19, 2018 07:13AM Bristol-Myers Squibb (BMY) Reports Clinical Research Collaboration with Gritstone Oncology to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Jul 19, 2018 07:00AM Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Jul 11, 2018 07:00AM Bristol-Myers Squibb (BMY) Opdivo + Low-Dose Yervoy is First Immuno-Oncology Combination Approved for Some MSI-H/dMMR mCRC Patients
Jul 11, 2018 06:59AM Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a
Jul 5, 2018 07:00AM Bristol-Myers Squibb (BMY) Says EC Approved Expanded Indication for Sprycel
Jul 5, 2018 06:59AM European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Jun 29, 2018 07:54AM Bristol-Myers Squibb (BMY) Announces Positive CHMP Opinion Recommending Approval of Opdivo for Adjuvant Treatment of Adult Patients with Melanoma
View More Recent Stories View Older Stories